Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the DNA Repair Drugs Market Expected to Be in 2029?

The market size of DNA repair medications has seen a significant expansion in recent times. Projected to escalate from $10.78 billion in 2024 to $13 billion in 2025, it presents a compound annual growth rate (CAGR) of 20.6%. The rise during the previous years can be traced back to the enhanced comprehension of DNA repair procedures, growth in cancer studies, changes in regulations surrounding pharmaceuticals, a surge in genetic disorder cases, and the broadening scope of personalized medicine.

The market size for DNA repair drugs is predicted to experience a swift expansion in the approaching years, escalating to “$26.77 billion in 2029 with a compound annual growth rate (CAGR) of 19.8%”. This surge during the forecast period is largely due to the creation of targeted therapies for DNA repair, the growing emphasis on precision medicine, an increase in the elderly population, and enhanced funding for the development of DNA repair drugs. Key trends for the forecast period involve the integration of artificial intelligence in drug discovery for DNA repair, the development of combination therapies aimed at DNA repair pathways, a focus on gene editing technologies, customized treatment plans based on DNA repair profiles, and an increase in clinical trials for DNA repair drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12200&type=smp

What Are The Contributors To Demand In The DNA Repair Drugs Market?

The increasing incidence of cancer is anticipated to drive the expansion of the DNA repair drug market in the future. Cancer is a disease type which can develop in almost any organ or tissue, when cells deviate from their normal growth pattern, ignoring their typical boundaries and grow uncontrollably possibly invading nearby body parts or even spreading to other organs. This uptick in cancer cases is mainly attributable to factors such as smoking, exposure to radiation, obesity, carcinogens, and genetic mutations. Preventing cancer involves disrupting the DNA’s self-repair mechanism which halts the proliferation and results in the death of cancer cells. For example, according to data from Australia’s government agency, the Australian Institute of Health and Welfare, there was a considerable increase in cancer diagnosis within the country, from 160,570 cases in 2022 to 164,694 in 2023, recorded in July 2024. This upward trajectory underscores the escalating rates of cancer in the nation. Hence, the growing cancer rates are fueling the expansion of the DNA repair drug market.

The dna repair drugs market covered in this report is segmented –

1) By Drug Type: Olaparib, Rucaparib, Niraparib, Talazoparib, Other Drugs

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

3) By Application: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Other Applications

Subsegments:

1) By Olaparib: Tablets, Capsules, Combination Therapies

2) By Rucaparib: Tablets, Monotherapy, Combination with Other Cancer Treatments

3) By Niraparib: Capsules, Extended-Release Formulations, Maintenance Therapy Applications

4) By Talazoparib: Capsules, Combination with Immunotherapy, High-Dose and Low-Dose Options

5) By Other Drugs: Experimental PARP Inhibitors, Generic and Biosimilar Versions, Next-Generation DNA Damage Response (DDR) Inhibitors

What Trends Are Currently Influencing Growth In The DNA Repair Drugs Market?

The emergence of product innovation is becoming a significant trend in the DNA repair drugs market. Premier companies in this industry are creating novel products to maintain their market standing. For instance, in June 2023, AstraZeneca PLC, a biopharmaceutical firm based in the UK, attained approval in the United States for Lynparza plus abiraterone to combat BRCA-mutated metastatic castration-resistant prostate cancer. Lynparza (olaparib) is the pioneer PARP inhibitor and the inaugural targeted drug to obstruct the DNA damage response (DDR) in cells or tumors without HRR (homologous recombination repair).

Who Are The Top-Ranked Companies In The DNA Repair Drugs Market Today?

Major companies operating in the DNA repair drugs market include Pfizer Inc., Johnson & Johnson Private Limited, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Biogen Inc., Ono Pharmaceutical Co. Ltd., Jiangsu HengRui Medicine Co. Ltd., BioMarin Pharmaceutical Inc., Genentech Inc., ClovisOncology Inc., Karyopharm Therapeutics Inc., Repare Therapeutics Inc., Intellia Therapeutics Inc., C4 Therapeutics Inc., Precision BioSciences, Artios Pharma Limited, FoRx Therapeutics AG, Onxeo SA, CRISPR Therapeutics AG

https://www.thebusinessresearchcompany.com/report/dna-repair-drugs-global-market-report

How Is DNA Repair Drugs Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the DNA repair drugs market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the DNA repair drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12200&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model